Novel oral anticoagulants (OAC) are being increasingly used. We describe a case of increased bleeding tendency resulting from probable drug interaction between rivaroxaban and topical miconazole. Recognition of this possible interaction is important during concomitant use to prevent adverse outcome arising from overanticoagulation.
INTRODUCTION
While the potential for drug interaction with warfarin is well known, little is known about the clinically significant drug interaction of novel oral anticoagulants (OAC) with topical use of miconazole. We describe a patient on rivaroxaban who presented with bleeding complication resulting from drug interaction with topical miconazole cream.
CASE REPORT
A 79 year-old man presented with a two-day history of extensive bruises and prolonged bleeding from an accidental skin break while being nursed. He had past medical history of diabetes mellitus, ischaemic heart disease and atrial flutter, for which he was treated with rivaroxaban 15 mg twice a day for past three months without clinical issue. Two weeks prior to presentation he was prescribed twice-daily topical miconazole cream (2%) for intertriginous candidiasis of the feet. He was haemodynamically stable on examination but was noted to have extensive ecchymoses over his anterior chest wall, arms and legs ( Fig. 1) . A small skin break was seen at upper chest wall with continuous slow oozing of blood despite direct pressure. His haemoglobin level had dropped to 11.7g/dL from his baseline of 13.5g/dL, which was checked two weeks prior to admission. His estimated creatinine clearance was 44ml/min and had not worsened from baseline. Prothrombin time (PT) was 13 seconds (normal range, 9.9-11.4 seconds) and activated partial thromboplastin time (aPTT) was 33 seconds (normal range, 25.7-32.9 seconds). Bleeding subsequently stopped with discontinuation of rivaroxaban and pressure bandaging. Repeat testing of haemoglobin level showed stabilisation and blood transfusion was not required.
DISCUSSION
Rivaroxaban is one of the novel OACs approved for use in nonvalvular atrial fibrillation or venous thromboembolism in Singapore, with benefits of rapid onset and generally does not require routine monitoring. Rivaroxaban is metabolised via cytochromes P450 3A4 (CYP3A4), with in vitro studies supporting the involvement of P-glycoprotein (P-gp) as the responsible active transporter in renal secretion of rivaroxaban. Antifungal imidazole derivatives such as ketoconazole, miconazole and clotrimazole have been shown to demonstrate significant inhibition of cytochromes P450 1 . Miconazole, a combined P-gpand strong CYP3A4-inhibitor, can potentially cause Proceedings of Singapore Healthcare  Volume 24  Number 2  2015 significant drug interaction and increase rivaroxaban concentration 2 . Topical miconazole has potential to be absorbed and interfere with systemic drugs, and has been documented in several case reports to interfere with warfarin 3 . Systemic absorption appears to be enhanced when miconazole is applied under occlusion on large surface, close to mucous membranes or in cases of intertrigo skin lesions 4 . However, interaction between topical miconazole and rivaroxaban has not been reported. Based on the adverse drug reaction (ADR) probability scale, the likelihood of a drug interaction between rivaroxaban and absorbed topical miconazole is probable 5 . There is little data on the effect of rivaroxaban on coagulation screen using reagents of different sensitivity. Prothrombin time, as compared to aPTT, has a more sensitive concentration response to rivaroxaban but there is marked variability between PT reagents. With an appropriate reagent with known sensitivity, PT level can be used for estimating the relative degree of anticoagulation intensity due to rivaroxaban, but it is not recommended to be used for determining drug level 6 . A rivaroxabancalibrated anti-factor Xa chromogenic assay is the preferred method for measuring plasma rivaroxaban concentration 7 , however, this is not widely available and is not currently being used in our institution.
In summary, the use of topical miconazole may have significant drug interaction with rivaroxaban resulting in adverse event from over-anticoagulation. The prescribing clinician should be aware of this possible interaction and exercise closer monitoring if simultaneous use is indicated.
